by Jennifer Lines, PharmD Candidate, PCCA Clinical Services Intern, and Catherine Henderson, PharmD, PCCA Clinical Compounding Pharmacist Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have revolutionized metabolic health and weight management, leading to a host of new weight loss wonder drugs
The combination of GLP-1, GIP, and glucagon receptor activation produces complex effects on blood glucose
Clinical evidence indicates they may slow the progression of diabetic kidney disease, preserving renal health over the long term
It's the first and only oral GLP-1 drug
In March 2026, topline results from the TRANSCEND-T2D-1 trials showed that participants with Type 2 diabetes achieved an average A1C reduction of up to 2.0% and lost nearly 17% of their body weight over 40 weeks
It is a timely process as our bodys collagen stops its production typically at the age of 30 to 40